WRAL Tech Wire

 Quintiles, DCRI shine in CRO industry survey

Quintiles and the Duke Clinical Research Institute are very different providers of clinical trial services but pharma executives give both high marks. Learn what makes them stand out.

ISR 2013 CRO Benchmarking Report

 Raleigh-based PRA International eyes public offering

Another life science services firm in the Triangle, PRA International, may follow in the footsteps of a bigger rival - Quintiles - by offering stock in order to raise capital. Just two years ago, PRA was at the center of takeover rumors in the range of $1 billion.

PRA's corporate timeline

 New drug model? Quintiles to develop compounds with Merck Serono

Fresh off an IPO that produced $1 billion for investors and the company, Quintiles on Wednesday announced a drug development deal in which it will work with Germany-based Merck Serono. But this contract is much different from others in which Quintiles shared some of the financial risk for new drug development. WRALTechWire Insiders get the story beyond the press release.

Drug development

 Quintiles IPO tops $1 billion, including overallotment

Quintiles completes its IPO selling 27.2 million shares, including the overallotment sold by investors who took stakes in Quintiles when it was private. Read just how much they stand to gain from the additional sale.

 Quintiles made plans to cut 400 jobs as it geared up for IPO

With its stock trading at a new high on Tuesday, Quintiles disclosed before the markets opened in a regulatory filing that it set aside $15 million to cover the costs of "restructuring" 400 workers.

Celebration day: Quintiles' founder rings open NYSE trading

Chairman and co-founder Dr. Dennis Gillings joins his company's executive management team for the ringing of the opening bell on the NYSE on Friday. Quintiles executed the biggest IPO in Triangle history on Thursday.

 As Quintiles' Gillings rings opening bell, SciQuest CEO recalls the feeling

Dennis Gillings, who started Quintiles in a trailer more than 30 years ago, rings the opening bell on the New York Stock Exchange today to celebrate the giant's return to public markets. Stephen Wiehe, who led SciQuest through a similar private-to-public Odyssey, recalls the "humbling" ringing bell honor.

Stphen Wiehe claps after opening Nasdaq

 After IPO, Quintiles ready for more scrutiny, COO says

Following Quintiles initial public stock offering, Chief Operating Officer John Ratliff gave WRAL Tech Wire an interview from the New York Stock Exchange. Read what he has to say about the now public company.

John Ratliff

 Quintiles prices its stock offering at $948M - Biggest IPO ever in Triangle

Shares in the world's largest life science services company are expected to begin trading Thursday on the New York Stock Exchange with an opening price of $40.

Quintiles, from trailer to global company

 Does Dennis Gillings really deserve his big payday as Quintiles goes public?

Financial expert Bob Broda takes a look at Quintiles' updated IPO offering, the big payday for co-founder and Chairman Dennis Gillings, and whether the stock is appealing to investors. Does Gillings deserve the cash out? Is Quintiles a good "buy"?

Quintiles, from trailer to global company

 Quintiles ups IPO target in seeking $900M through stock offering

Quintiles, the world's largest life science services company, is seeking more than $900 million through a stock offering. Find out the price per share and how many shares Chairman Dennis Gillings wants to sell.

Quintiles' cover image for IPO filing

 No Quintiles IPO yet but new filing offers 1Q details

While Quintiles' latest filing doesn't give any pricing details on the proposed IPO, the company did disclose partial, preliminary and unaudited first quarter financials.

 Quintiles receives top vaccine industry award for 2nd straight year

The world's largest life science services firm is named the top clinical research organization by the Vaccine Industry Excellence Awards for the second consecutive year.

 Quintiles selected as Bristol-Myers 'preferred provider'

 Quintiles IPO pledges $25M payment to private equity; shareholders already reaping dividends

When Quintiles goes public, founder and Chairman Dennis Gillings and the private equity firms who together own the vast majority of the company stand to gain $25 million straight away without even selling a single share of their Quintiles stock.

Quintiles' headquarters

 Quintiles spent $280M on M&A in the year leading up to IPO

In the 16 months prior to filing for an initial public offering, Quintiles spent more than $280 million buying companies that bolstered the Durham clinical research organization's capabilities in clinical testing, genomics and drug commercialization.

 Cashing in: Quintiles IPO comes as industry rebounds

Quintiles IPO rumors were brewing for months but if you're wondering why now is the right time for a filing, take a look at the financial performance of the Durham contract research organization's publicly-traded peers.

Quintiles' headquarters

 Inside Quintiles' IPO strategy: Positioning giant for growth

On Friday, Quintiles disclosed plans to become a public company again through a stock offering of an estimated $600 million. Finance expert Bob Broda, who leads an RTP firm focused on compliance issues with an emphasis on Sarbanes-Oxley, reviewed the Quintiles filing at the request of WRAL Tech Wire and offers his views on where Quintiles stands plus where it seems to be headed.

Quintiles' headquarters

 Quintiles files for $600M IPO

Quintiles aims to go public again. The Durham CRO filed plans for a $600 million initial public stock offering on Friday.

 Sources: Quintiles picks 3 banks to handle IPO

Quintiles, which went private in 2008, has selected three banks to handle a return to the public markets, sources tell Reuters.

Quintiles' headquarters